IL17A and irritable bowel syndrome: Mice lacking SFB in their microbiotahave weaker immune responses and are more vulnerable to infectionslike Citrobacter rodentium due to weakenedintestinal barrier function.29 Moreover,a clinical trial administering a neutralizing IL-17A monoclonal antibodyto patients with IBD did not provide protection and was linked toincreased adverse events, including Candida albicans infection.